NASDAQ:ALGS Aligos Therapeutics (ALGS) Stock Price, News & Analysis $5.54 +0.03 (+0.54%) Closing price 09/28/2026 04:00 PM EasternExtended Trading$5.50 -0.04 (-0.81%) As of 09/28/2026 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Aligos Therapeutics Stock (NASDAQ:ALGS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aligos Therapeutics alerts:Sign Up Key Stats Today's Range$5.18▼$5.5450-Day Range$4.08▼$7.6552-Week Range$3.98▼$13.69Volume79,512 shsAverage Volume49,331 shsMarket Capitalization$34.57 millionP/E RatioN/ADividend YieldN/APrice Target$38.50Consensus RatingModerate Buy Company Overview Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for chronic liver diseases, viral infections and related conditions. The company uses its research platforms to discover and advance small-molecule therapies designed to address significant unmet medical needs. Its development programs have included treatments for chronic hepatitis B, metabolic dysfunction-associated steatohepatitis (MASH) and viral respiratory diseases. The company’s hepatitis B pipeline has included capsid assembly modulators, while its MASH efforts have included therapies intended to improve liver health and reduce disease progression. Aligos has also pursued antiviral programs targeting coronaviruses and other infectious diseases. Founded in 2018, Aligos Therapeutics is headquartered in South San Francisco, California. Its programs are developed through clinical research and collaborations intended to support potential commercialization in international markets. The company is led by President and Chief Executive Officer Lawrence M. Blatt.AI Generated. May Contain Errors. Read More Aligos Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreALGS MarketRank™: Aligos Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 488th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingAligos Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAligos Therapeutics has a consensus price target of $38.50, representing about 594.9% upside from its current price of $5.54.Amount of Analyst CoverageAligos Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Aligos Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aligos Therapeutics are expected to grow in the coming year, from ($6.81) to ($5.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aligos Therapeutics is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aligos Therapeutics is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAligos Therapeutics has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aligos Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.12% of the float of Aligos Therapeutics has been sold short.Short Interest Ratio / Days to CoverAligos Therapeutics has a short interest ratio ("days to cover") of 15.35, which indicates bearish sentiment.Change versus previous monthShort interest in Aligos Therapeutics has recently increased by 7.57%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAligos Therapeutics does not currently pay a dividend.Dividend GrowthAligos Therapeutics does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment1.26 News SentimentAligos Therapeutics has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Aligos Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for ALGS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aligos Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders7.80% of the stock of Aligos Therapeutics is held by insiders.Percentage Held by Institutions60.43% of the stock of Aligos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aligos Therapeutics' insider trading history. Receive ALGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aligos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALGS Stock News HeadlinesAligos Therapeutics (NASDAQ:ALGS) Upgraded at Jefferies Financial GroupSeptember 28 at 1:12 AM | americanbankingnews.comAligos Therapeutics Amends Long-Term Headquarters Lease AgreementSeptember 15, 2026 | tipranks.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it. | Banyan Hill Publishing (Ad)Aligos Therapeutics Shares Rise 7.6% Premarket Following Recent Company UpdatesSeptember 2, 2026 | finance.yahoo.comAligos Therapeutics to Present at the Cantor Global Healthcare ConferenceSeptember 2, 2026 | globenewswire.comAligos Hepatitis B Trial Completion: What Phase 1 Liver Data Mean for ALGS InvestorsAugust 21, 2026 | tipranks.comAligos Advances Hepatitis B Program With Completed Phase 1 Kidney Impairment StudyAugust 21, 2026 | tipranks.comAligos Therapeutics Inc.August 15, 2026 | marketwatch.comSee More Headlines ALGS Stock Analysis - Frequently Asked Questions How have ALGS shares performed this year? Aligos Therapeutics' stock was trading at $9.32 at the beginning of 2026. Since then, ALGS shares have decreased by 40.6% and is now trading at $5.54. How were Aligos Therapeutics' earnings last quarter? Aligos Therapeutics, Inc. (NASDAQ:ALGS) released its quarterly earnings results on Thursday, August, 6th. The company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($1.09) by $0.95. The company had revenue of $27.78 million for the quarter, compared to the consensus estimate of $24.68 million. Aligos Therapeutics had a negative net margin of 241.01% and a negative trailing twelve-month return on equity of 160.72%. When did Aligos Therapeutics' stock split? Shares of Aligos Therapeutics reverse split on the morning of Monday, August 19th 2024.The 1-25 reverse split was announced on Thursday, August 15th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Aligos Therapeutics IPO? Aligos Therapeutics (ALGS) raised $150 million in an initial public offering on Friday, October 16th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P.Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO and Cantor was co-manager. How do I buy shares of Aligos Therapeutics? Shares of ALGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aligos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aligos Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Taiwan Semiconductor Manufacturing (TSM) and Adverum Biotechnologies (ADVM). Company Calendar Last Earnings8/06/2026Today9/29/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ALGS's financial health is in the Yellow zone, according to TradeSmith. ALGS has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ALGS CIK1799448 Webwww.aligos.com Phone800-466-6059FaxN/AEmployees82Year Founded2018Price Target and Rating Average Price Target for Aligos Therapeutics$38.50 High Price Target$50.00 Low Price Target$20.00 Potential Upside/Downside+594.9%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($7.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$24.19 million Net Margins-241.01% Pretax Margin-230.81% Return on Equity-160.72% Return on Assets-92.30% Debt Debt-to-Equity RatioN/A Current Ratio2.19 Quick Ratio2.19 Sales & Book Value Annual Sales$2.19 million Price / Sales15.79 Cash FlowN/A Price / Cash FlowN/A Book Value$8.67 per share Price / Book0.64Miscellaneous Outstanding Shares6,240,000Free Float5,758,000Market Cap$34.57 million OptionableNo Data Beta2.34 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:ALGS) was last updated on 9/29/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
